GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B upfront, with potential for an additional $150M ...

The sale represents nearly 7.7% of issued share capital of Haleon, which was created by the merger of GSK and Pfizer's ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares closed today ...

The sale represents nearly 7.7% of the issued share capital of Haleon, which was created by the merger of GSK (GSK.L), opens new tab and Pfizer's consumer healthcare businesses in 2019.

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

The sale represents nearly 7.7% of the issued share capital of Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

Pfizer is a New York-based pharmaceutical and biotechnology firm. Haleon was formed in 2019 as a joint venture of Pfizer and GSK PLC's consumer health businesses. It was listed on the London Main ...

GSK has also been selling down its holding, and offloaded its remaining 4.2% stake in May last year (Alliance News) - Pfizer Inc is selling 700 million shares in Haleon PLC, more than halving its ...